Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Table 2 Characteristics of the hinges in the trends of CD4+ T-cell counts (two-phase linear regression model)

NNRTI group N = 436/627 (69.4%)			NRTI group N = 145/217 (66.8%)
Time of the hinge relative to the switch (categories)
Before the switch	≤ 180 days from the switch	>180 days from the switch	Before the switch	≤ 180 days from the switch	>180 days from the switch
N = 325/436 (74.5%)	N = 31/436 (7.1%)	N = 80/436 (18.3%)	N = 118/145 (81.4%)	N = 9/145 (6.2%)	N = 18/145 (12.4%)
Increasing CD4+ trend after the hinge relative to the pre-switch trend (categories)
N = 210/325 (64.6%)	N = 7/31 (22.6%)	N = 18/80 (18.7%)	N = 68/145 (46.9%)	N = 3/9 (33.3%)	N = 1/18 (5.5%)
Estimates of the increasing trend (median CD4+/mm ³ */day, IQR or min-max/individual ^$ values where indicated)**
1.0003	1.0003	1.0005	1.0003	*min-max:
1.0002 to 1.0005	1.0002 to 1.0082	1.0001 to 1.0015	1.0002 to 1.0004	1.0001 to 1.00025	^$1.0001
Stationary CD4+ trend after the hinge relative to the pre-switch trend (categories)
N = 68/325 (20.9%)	N = 8/31 (25.8%)	N = 20/80 (25%)	N = 32/145 (22.1%)	N = 3/9 (33.3%)	N = 5/18 (27.8%)
Decreasing CD4+ trend after the hinge relative to the pre-switch trend (categories)
N = 47/325 (14.5%)	N = 16/31 (51.6%)	N = 45/80 (56.2%)	N = 18/145 (12.4%)	N = 3/9 (33.3%)
					N = 12/18 (66.7%)
Estimates of the decreasing trend (median CD4+/mm ³ */day, IQR or min-max values where indicated)**
-1.0002	-0.99981	-1.0007	-1.0003	*min-max:	-1.0004
-1.0001 to -1.0004	-0.99959 to -0.999945	-1.0029 to 1.0003	-1.0005 to -1.0002	-0.99585 to -0.99988	-1.0015 to -1.0003

ISSN: 1471-2334